With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy

The WAC price of Winrevair is $14,000 per vial

The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.

pulmonary disease
Merck's sotatercept was approved by FDA for PAH • Source: Shutterstock

More from New Products

More from Scrip